life scienc tool diagnost
ep ahead consensu dgx ep
exceed higher revenu off-set lighter compar
profit factor line drive beat despit upsid
re-affirmed guidanc call full year ep
rais ep reflect beat
stronger anticip volum captur off-set lower profit
experi also fine tune oper forecast conform
new adjust calcul exclud amort expens across entir
 vs exclud adj ep line pt move
ebitda higher view
volum price ahead plan profit fall short revenu growth
forecast stronger volum vs estimate
volum captur rev/accn well ahead
improv gross margin drop bp still higher
plan bp admin expens rose bp
compar basi wors forecast bp despit
bp plan flow million facilit million
share repurchas million acquisit million dividend
share ralli dgx share retrench high april
vs democrat presidenti candid advoc
medicar share edg higher today better organ volum
price manag note acceler trend past
month also encourag yesterday prefer laboratori
network pln announc clinic lab updat could drive
meaning increment volum low cost provid like labcorp
increment pressur clinic lab outsid pln scope
potenti spur consolid across industri risk includ
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
provid diagnost test informatin
price apr rate neutral target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
better fundament perform could come faster
organ growth gain in-network statu
sentiment could drive upsid target price blue sky
scenario
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
 close
organ growth robust revenu growth forecast
acceler trend notabl experienc bp tailwind
favor weather off-set one less sell day quarter bp
headwind impli bp normal organ growth experi well
intern organ forecast manag larg attribut organ growth
strength increas access increment million in-network member
contract bcb new jersey bcb georgia also note stabl
demand trend across broader industri
term cadenc contract shift experienc initi healthi kick-off
new contract januari driven educ effort sequenti
improv februari march continu build throughout year
line previou commentari remind estim three new
contract repres billion revenu opportun aim captur
share in-lin current market posit within independ lab
segment also note experienc partial offset loss non-
exclus aetna contract dynam larg embed expect
view manag note recent stabil even recoveri
potenti lt volum boost prefer lab network also
effect juli broadli anticip labcorp quest diagnost
along
bioreference/genedx mayoclin laboratori smaller cohort lab
previous expect posit larger nation lab
dgx contract price like lower averag given size
natur contract highlight price alreadi lock
chang particip pln broadli believ
disproport offset steer increment volum effici servic provid
labcorp price alreadi presum lower like
embed expect extent view said
incorpor meaning volum lift pln await detail
clinic laboratori outsid unh pln scope would turn face increment pressur
potenti drive consolid across industri exampl provid
patholog servic biopsi would offer discount pln
laboratori vs non-pln in-network laboratori even greater discount rel
out-of-network lab new pln consist view health plan
increasingli attempt address lab cost trend remain high dd believ
labcorp quest offer solut rel low cost provid
begin trend believ unh pln could begin broader
market trend payor seek way better control clinic laboratori spend healthcar
expenditur area rel unmanag also note discuss
progress nation payor similar network note
historically-speak prefer lab network focus sole price
network consid broader rang criteria includ data servic requir
well cost
ameripath/dermpath
subsidiari
rev/accn better also highlight revenue/access ahead
estim repres improv experi year
year declin attribut increas reimburs pressur relat
pama well higher patient concess bp relat patient
concess continu expect higher level go-forward basi patient
respons increas though hope lap headwind
term payor denial recent receiv posit news nation payor
deni same-day servic payor reimburs
appropri relev servic though await implement updat
polici expect nt note lap vitamin polici chang nation
payor aetna plan implement similar polici aetna allow
bill patient deni test provid off-set
pama relief updat plan worst case scenario current
factor cut continu fight better overal
outcom today april american clinic laboratori associ acla
present oral argument court appeal aim overturn
prior judg decis throw case due jurisdict issu remind
septemb district court district columbia dismiss lawsuit
brought forth acla reform propos rate cut part clinic lab
fee schedul clf protect medicar act pama court held
acla testimoni rais pertin question ultim conclud
author act manner
term potenti outcom hear judg may either overturn prior
judg decis point acla present full case court hear
judg agre prior rule point may choos go
suprem court appeal case acla also continu work congress
potenti drive legisl resolut note hope full repeal
pama rather comprehens measur commerci market price
pama round ii data collect fall implement larg
nation low-cost provid disproportion skew previou analysi
industri dynam catalyz consolid number fundament chang
clinic market place underway includ pama reimburs chang payor focu
lab spend manag prefer lab network increas
price transpar websit drive consolid long-await
dynam view pama remain meaning driver nt consolid
implic associ reimburs cut becom much visibl smaller
player fact smaller laboratori higher price cost larger nation lab
like experi signific impact exampl trident usa health
servic lead nurs home focus laboratori meaning medicar exposur
file bankruptci sever week ago provid indic potenti impact
smaller player note comment activ dialogu
number system
compani mention price
labcorp america lh
